EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary detection of high-risk HPV DNA to enhance cervical cancer screening in developing countries

Novia Syari Intan iD, Revata Utama iD, Dewi Wulandari, Reiva Wisdharilla, Shafira Mutia Khanza, Muhamad Rifki Ramadhan, Indah Suci Widyahening, Neni Nurainy, Rini Mulia Sari, Andrijono

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01938-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Novia Syari Intan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nusantics, PT Riset Nusantara Genetika, East Jakarta, Indonesia. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, DNA, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PT Bio Farma, Nusantics, PT Riset Nusantara Genetika.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To increase cervical cancer screening capacity and participation, we evaluated the performance of the newly developed high-risk human papillomavirus (hrHPV) ReadyMix qPCR Kit for detecting hrHPV in urine samples while genotyping for HPV-16, HPV-18, and HPV-52. A total of 876 samples were used to assess the performance of the hrHPV ReadyMix qPCR Kit in detecting hrHPV in standard cervical swab samples compared with that of the Roche Cobas 6800 HPV system. hrHPV detection in urine was compared with that in corresponding paired cervical swab samples. The sensitivity of the hrHPV ReadyMix qPCR Kit for HPV detection in cervical swab samples was 96.55%, and the specificity was 99.87%. Despite higher cycle threshold (Ct) values, urine samples demonstrated 80.88% sensitivity and 100.00% specificity compared with cervical swab samples. Our method enables population-based hrHPV analysis, with a 6.62% HPV prevalence determined via cervical swab samples and a 6.28% HPV prevalence determined via urine samples. Furthermore, the hrHPV ReadyMix qPCR Kit presented comparable HPV type distributions in urine samples and the ability to genotype HPV-16 and HPV-18 to those obtained via the Roche Cobas 6800 HPV system. Self-collected urine samples tested using the hrHPV ReadyMix qPCR Kit demonstrated a diagnostic accuracy of 98.48% for detecting hrHPV. This study highlights the potential of the hrHPV ReadyMix qPCR Kit to enhance cervical cancer screening, offering valuable insights for future interventions. IMPORTANCE This study demonstrated that urinary detection of high-risk HPV DNA using the hrHPV ReadyMix qPCR Kit is an effective alternative for hrHPV screening. This non-invasive approach holds significant potential for large-scale screening, particularly in underserved populations. Integrating urine-based hrHPV testing into screening programs could improve early detection efforts, thereby enhancing the prevention and control of cervical cancer in low-resource settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsEarly Detection of CancerDNA, ViralPapillomaviridaeUrineHumansFemaleSensitivity and SpecificityDeveloping CountriesAdultMiddle AgedGenotypeCervix UteriHuman papillomavirus 16Mass ScreeningHuman papillomavirus 18Real-Time Polymerase Chain Reaction

Stichwörter der Autor:innen

HPVHPV DNA testPathoScan hrHPVcervical cancerearly diagnosis of cancerhuman papillomavirusin vitro diagnostic medical devicesmultiplex PCRreal-time PCRself-samplingurine

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Nusantics, PT Riset Nusantara Genetika, East Jakarta, Indonesia.
  • Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia.
  • Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia.
  • Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia.
  • Translational Development of Life Science Product Division, PT Bio Farma, Bandung, Indonesia.
  • Surveillance and Clinical Research Division, PT Bio Farma, Bandung, Indonesia.

ORCID-Profile: Novia Syari Intan, Revata Utama

Förderung

  • PT Bio Farma
  • Nusantics, PT Riset Nusantara Genetika

Zitieren

APA

Intan, N. S., Utama, R., Wulandari, D., Wisdharilla, R., Khanza, S. M., Ramadhan, M. R., Widyahening, I. S., Nurainy, N., Sari, R. M., & Andrijono (2025). Urinary detection of high-risk HPV DNA to enhance cervical cancer screening in developing countries. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01938-24

Vancouver

Intan NS, Utama R, Wulandari D, Wisdharilla R, Khanza SM, Ramadhan MR, et al. Urinary detection of high-risk HPV DNA to enhance cervical cancer screening in developing countries. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01938-24

BibTeX
@article{Intan2025,
  author = {Intan, Novia Syari and Utama, Revata and Wulandari, Dewi and Wisdharilla, Reiva and Khanza, Shafira Mutia and Ramadhan, Muhamad Rifki and Widyahening, Indah Suci and Nurainy, Neni and Sari, Rini Mulia and Andrijono},
  title = {Urinary detection of high-risk HPV DNA to enhance cervical cancer screening in developing countries},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01938-24}
}
Kostenlos starten →